USMLE Content Outline
associated lymphoid tissue and bronchus-associated lymphoid tissue), anatomical locations of T and B lymphocytes . Cellular basis of the immune response and immunologic mediators . antigen processing and presentation in the context of MHC I and MHC II molecules (eg, TAP, beta-2 microglobulin), intracellular pathways, mechanisms by which MHC is
Download USMLE Content Outline
Information
Domain:
Source:
Link to this page:
Documents from same domain
Step 2 Clinical Skills (CS) - usmle.org
www.usmle.orgThe United States Medical Licensing Examination (USMLE), through its three Steps (Step 1, Step 2, and Step 3), assesses a physician's ability to apply knowl-
USMLE Content Outline
www.usmle.orgUSMLE® Content Outline A Joint Program of the Federation of State Medical Boards of the United States, Inc., and the National Board of Medical Examiners®
2018 BULLETIN of INFORMATION - United States …
www.usmle.org2018 bulletin of information a joint program of the federation of state medical boards of the united states, inc., and the national board of medical examiners®
Step Booklet Covers 2017 Step Booklet cover - …
www.usmle.org3 Introduction This booklet is intended to help you prepare for the Step 1 component of the United States Medical Licensing Examination ® (USMLE ). The information in this booklet, sample test
Step 3 Sample Questions November 2020 - USMLE
www.usmle.orginformation available in the USMLE Content Description and General Information booklet and by practicing with sample CCS cases before you take the Step 3 examination; the information and the practice materials are available on the USMLE Web site (www.usmle.org).
Step 1 - USMLE
www.usmle.orgStep 1 SAMPLE TEST QUESTIONS A Joint Program of the Federation of State Medical Boards of the United States, Inc., and National Board of Medical Examiners®
USMLE Physician Tasks/Competencies
www.usmle.orgA Joint Program of the Federation of State Medical Boards of the United States, Inc., and National Board of Medical Examiners® USMLE Physician Tasks/Competencies provides an outline of the tasks and competencies assessed throughout the sequence of USMLE examinations. While this outline is common to all exams, each Step has test ...
Your Test Result FAIL
www.usmle.orgUnited States Medical Licensing Examination® Step 1 Score Report FOR EXAMINEE USE ONLY. THIRD-PARTY USERS OF USMLE® SCORES SHOULD RELY SOLELY ON OFFICIAL TRANSCRIPTS RECEIVED DIRECTLY FROM THE EXAMINEE’S USMLE REGISTRATION ENTITY. NAME: Last Name, First Name USMLE ID: 0-000-000-0 TEST DATE: February 13, …
Step 2 Clinical Knowledge (CK) - USMLE
www.usmle.orgPatient scenarios for any Single Item or Sequential Item Set may be provided in either Vignette (paragraph) format, or in ... • generalized anxiety disorder • major depressive disorder. Medications: • citalopram. Allergies: ... (5 ft 7 in) (140 lb) • Appearance: awake and alert but distraught and fearful; patient says, "This was totally ...
Sample Questions, Step 1 - USMLE
www.usmle.org(C) Erythrocyte enzyme deficiency (H) Sickle cell disease (D) Erythropoietin deficiency (I) Sideroblastic anemia (E) Immunohemolysis (J) β-Thalassemia trait (Answer: D) NOTE: Some item types that appear on the Step 1 examination are NOT depicted in the sample items provided
Related documents
Lymphoma Diagnostic Work-up from a Lab Perspective
arup.utah.eduNon-Hodgkin lymphoma (NHL) 2. Hodgkin (disease) lymphoma 3. Multiple myeloma Lymphomas are solid tumors of the hematopoietic system. Neoplasms of lymphoid origin, typically causing lymphadenopathy
NATIONAL INSTITUTES OF HEALTH National Cancer Institute
seer.cancer.govICD-O-3 has been updated to include contemporary terminology. For example, the non-Hodgkin lymphoma section is now based on the World Health Organization Classification of Hematopoietic Neoplasms3. In the process of revising the morphology section, a Field Trial version was published and tested in both the United States and Europe.
Chapter 1 Overview of Hematologic Malignancies
www.ons.orgachieved in patients with Hodgkin lymphoma, treatment toxicities remain a significant source of morbidity and mortality for survivors of this disease (Hoppe, 1997). The most commonly noted causes of mortality are second malignant neoplasms and cardiovascular disease (Hoppe, 1997). While mortality from Hodgkin lymphoma be-